Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Young women with BRCA mutations feel differently about options for relationships, careers

A study published in the October issue of the American Journal of Nursing (AJN) found that young women who learn they have BRCA1 and BRCA2 gene mutations felt differently about options for relationships, treatment, childbearing and careers.

26 Sep 2012

Researchers discover genetics secrets of ovarian cancer tumors

A new discovery that sheds light on the genetic make up of ovarian cancer cells could explain why some women survive longer than others with this deadly disease.

25 Sep 2012

Molecular similarity between one sub-type of breast cancer and ovarian cancer

A team of scientists with The Cancer Genome Atlas program reports their genetic characterization of 800 breast tumors, including finding some of the genetic causes of the most common forms of breast cancer, providing clues for new therapeutic targets, and identifying a molecular similarity between one sub-type of breast cancer and ovarian cancer.

24 Sep 2012

Simple survey can effectively identify women with ovarian cancer symptoms

A simple three-question paper-and-pencil survey, given to women in the doctor's office in less than two minutes, can effectively identify those who are experiencing symptoms that may indicate ovarian cancer, according to a study by researchers at Fred Hutchinson Cancer Research Center.

24 Sep 2012

Most basal-like breast and ovarian tumors have similar genetic origins

The most comprehensive analysis yet of breast cancer shows that one of the most deadly subtypes is genetically more similar to ovarian tumors than to other breast cancers.

24 Sep 2012

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.

20 Sep 2012

APR-246 can restore function of defective p53 and activate apoptosis in cancer cells

The p53 gene plays a key role in the prevention of cancer, by blocking cell growth and triggering programmed cell death or apoptosis. If, however, p53 has mutated and become defective, the cancer cells can acquire the ability to evade apoptosis and become more resistant to therapy.

20 Sep 2012

Power of taxane-based chemotherapy drugs may be potentially underestimated

The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.

18 Sep 2012

Positive data from Aprea’s APR-246 Phase I/II study on blood or prostate cancer

Aprea today announced positive data from a completed Phase I/II clinical study with its investigational drug APR-246. The results from the study have been published in the Journal of Clinical Oncology.

18 Sep 2012

Study could reveal whether breast cancer patients with BRCA mutations are responsive to Veliparib

Ongoing research at the Methodist Cancer Center could reveal whether metastatic breast cancer patients with BRCA gene mutations are particularly responsive to a drug regimen that includes Veliparib, an investigational drug believed to hamper cancer cells.

15 Sep 2012

People with family history of certain diseases often underestimate their risk

People with a family history of certain diseases, including heart disease and diabetes, often underestimate their risk for developing them, even after completing a risk assessment and receiving personalized prevention messages, finds a new study in the American Journal of Preventive Medicine.

13 Sep 2012

Viewpoints: Questions Obama, Romney not likely to answer in debates; Disturbing news on tests for ovarian cancer

New evidence that women are more likely to be harmed than helped by screening tests for ovarian cancer is disturbing. The tests do nothing to prevent healthy women from dying from the usually fatal disease. Yet they often lead doctors to perform needless surgeries that cause serious complications in many patients.

13 Sep 2012

BRCA1/2 gene mutations lethal to human embryos

BRCA1/2 gene mutations, widely associated with breast and ovarian cancer risks in women, are, in principle, lethal to human embryos, according to new research conducted by three teams of researchers from the Center for Human Reproduction (CHR) in New York City, the Medical University Vienna in Vienna, Austria, and the Medical University Graz, Graz, Austria.

13 Sep 2012

Researchers identify many potential therapeutic targets for squamous cell lung cancers

A new paper published online in Nature holds out hope that people with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients.

10 Sep 2012

Drugs targeting protein TGF-β may be used to treat ovarian cancer

In the September issue of the Journal of Clinical Investigation, researchers at MD Anderson Cancer Center report that ovarian cancer cells activate the HOXA9 gene to compel stromal cells to create an environment that supports tumor growth.

5 Sep 2012

Study confirms link between hormone replacement therapy use and breast cancer

The Million Women Study is a study, conducted by UK researchers, of women's health analyzing data from more than one million women aged 50 and over. It is a collaborative project between Cancer Research UK and the National Health Service (NHS), with additional funding from the Medical Research Council (UK).

31 Aug 2012

Esperance completes EP 100 and paclitaxel Phase 2 combination trial on advanced ovarian cancer

Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP‑100 in combination with paclitaxel for patients with advanced ovarian cancer. EP‐100 is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

29 Aug 2012

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

Researchers discover mechanisms responsible for chemoresistance in ovarian cancer

The presence of multiple ovarian cancer genomes in an individual patient and the absence or downregulation of the gene LRP1B are associated with the development of chemoresistance in women with the high-grade serous cancer subtype of ovarian cancer whose disease recurs after primary treatment. These study results are published in Cancer Research, a journal of the American Association for Cancer Research.

16 Aug 2012

RNA-delivering nanoparticles allow rapid screening of new drug targets in mice

By sequencing cancer-cell genomes, scientists have discovered vast numbers of genes that are mutated, deleted or copied in cancer cells. This treasure trove is a boon for researchers seeking new drug targets, but it is nearly impossible to test them all in a timely fashion.

16 Aug 2012

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Young women with BRCA mutations feel differently about options for relationships, careers

Researchers discover genetics secrets of ovarian cancer tumors

Molecular similarity between one sub-type of breast cancer and ovarian cancer

Simple survey can effectively identify women with ovarian cancer symptoms

Most basal-like breast and ovarian tumors have similar genetic origins

Boehringer Ingelheim files MAA with EMA for afatinib approval

APR-246 can restore function of defective p53 and activate apoptosis in cancer cells

Power of taxane-based chemotherapy drugs may be potentially underestimated

Positive data from Aprea’s APR-246 Phase I/II study on blood or prostate cancer

Study could reveal whether breast cancer patients with BRCA mutations are responsive to Veliparib

People with family history of certain diseases often underestimate their risk

Viewpoints: Questions Obama, Romney not likely to answer in debates; Disturbing news on tests for ovarian cancer

BRCA1/2 gene mutations lethal to human embryos

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Drugs targeting protein TGF-β may be used to treat ovarian cancer

Study confirms link between hormone replacement therapy use and breast cancer

Esperance completes EP 100 and paclitaxel Phase 2 combination trial on advanced ovarian cancer

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Researchers discover mechanisms responsible for chemoresistance in ovarian cancer

RNA-delivering nanoparticles allow rapid screening of new drug targets in mice

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in